A delegation of senior representatives from the U.S. Department of Health and Human Services (HHS) and the U.S. Food and Drug Administration (FDA) recently visited the Indian manufacturing plant of Amneal Pharmaceuticals, Inc., a prominent US-based pharmaceutical company.
The delegates, who were in India to attened the G20 Health Ministers’ meeting in Gandhinagar, visited the site located in a quaint village in India’s Gujarat, Matoda.
The visiting delegation included notable figures such as Loyce Pace, Assistant Secretary for Global Affairs at the U.S. Department of HHS, responsible for shaping worldwide priorities and policies. Genessa Giorgi, U.S. HHS Health Attaché to India, Dr Sarah McMullen, India Country Director for the U.S. FDA, and Dr. H G Koshia, Commissioner for the India Food and Drug Control Agency (FDCA) in Gujarat were also part of the delegation.
During the visit, the delegation gained insights into the company's cutting-edge automation technology and its capabilities to produce complex medicines. The tour also highlighted the intricacies of pharmaceutical manufacturing, underlining the significance of investing in technology to ensure the availability of safe and effective medications, a release stated.
Amneal’s co-chief executive officers, Chirag Patel and Chintu Patel said on the occasion, “Amneal is a global pharmaceuticals company focused on providing access to affordable, essential medicines. Across our large and diversified product portfolio, we provide key therapies to meet the needs of patients.”
“We are proud to participate in this important visit to share our role in delivering safe and effective pharmaceuticals around the world. We look forward to continuing to engage on the key issues that impact the U.S. pharmaceutical industry’s ability to serve patients, including drug shortages,” they added.
ADVERTISEMENT
ADVERTISEMENT
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login